MIRA Pharmaceuticals, Inc.

Equities

MIRA

US60458C1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 26/06/2024 am IST			5-day change	1st Jan Change
0.71 ^USD	-0.01%		0.00%	-32.38%

24/06	MIRA Pharmaceuticals, Inc. Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing	CI
10/06	MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year	CI

MIRA Pharmaceuticals, Inc. has completed an IPO in the amount of $8.925 million.

August 02, 2023 at 09:30 am IST

MIRA Pharmaceuticals, Inc. has completed an IPO in the amount of $8.925 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,275,000
PriceRange: $7
Discount Per Security: $0.49

Latest news about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing	24/06	CI
MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year	10/06	CI
Sector Update: Health Care Stocks Fall Late Afternoon	30/05	MT
Sector Update: Health Care Stocks Retreat Wednesday Afternoon	29/05	MT
Mira Pharmaceuticals Says US DEA Finds Marijuana Analog a Non-Controlled Substance	29/05	MT
MIRA Pharmaceuticals, Inc. Announces DEA Rules Mira-55, A Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as A Controlled Substance	29/05	CI
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, A Differentiated Oral Ketamine Analog	20/05	CI
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Mira Pharmaceuticals, Inc. Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission	02/04	CI
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Mira Pharmaceuticals Inc. Announces Appointment of Itzchak Angel as Chief Scientific Advisor	21/03	CI
MIRA Pharmaceuticals, Inc. Announces Management Changes	14/03	CI
MIRA Pharmaceuticals, Inc. Provides Updated Information Regarding the Patented, Pre-Clinical Drug Candidate Molecule Known as Mira1a	08/03	CI
Certain Stock Options of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	30/01	CI
Certain Common Stock of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	30/01	CI
Certain Warrants of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	30/01	CI
MIRA Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis from the Board of Directors and as Part-Time General Counsel	18/01	CI
MIRA Pharmaceuticals, Inc. Releases Breakthrough Data from Artificial Intelligence Simulations	04/12	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	21/11	MT
Top MIdday Gainers	21/11	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	21/11	MT
Sector Update: Health Care	21/11	MT
Mira Pharmaceuticals Signs Licensing Deal for Ketamine Analog Ketamir-2	20/11	MT
MIRA Pharmaceuticals, Inc. Approves Appointment of Michael Jerman to the Board	20/11	CI
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI

Chart MIRA Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MIRA PHARMACEUTICALS, INC.	-32.38%	10.5M
MODERNA, INC.	+38.36%	52.5B
LONZA GROUP AG	+36.73%	39.31B
IQVIA HOLDINGS INC.	-8.63%	39.01B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	28.2B
CELLTRION, INC.	-11.17%	26.57B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.2B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.62B
BIO-TECHNE CORPORATION	-5.30%	11.74B

Other Biotechnology & Medical Research